Donna L. Forrest

Who participates in myeloma trials? clinical and geographic predictors of access and outcomes in British Columbia, Canada.

Hong Li, Timothy Wong, A. MAUREEN ROUHI, Christopher Paul Venner et autres

Abstract Introduction: Clinical trials (CTs) are essential for advancing evidence-based treatment in multiple myeloma (MM), offering patients early access to novel therapies. British Columbia (BC), a geographically large province, more than twice the size of France, has centralized CTs in major urban …

ca (code pays fourni par la source)

Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population

Eric J. Zhao, Sujaatha Narayanan, Florian C. Kuchenbauer, Stephen H. Nantel et autres

Abstract Introduction The 2022 European Leukemia Network (ELN) risk stratification system for acute myeloid leukemia (Dohner et al, Blood, 2022) added several myelodysplasia-related (MR) genetic mutations to the adverse risk category, assigned FLT3-ITD mutations to the intermediate risk category, and designated bZIP …

ca (code pays fourni par la source)

Upfront comprehensive donor search overcomes the impact of poor search prognosis, irrespective of racial background

Fei Fang, Ryan Vethanayagam, Karen R. Sherwood, James H. Lan et autres

Abstract Introduction: Access to suitably matched donors remains a major barrier to allogeneic hematopoietic cell transplantation (HCT), particularly for non-White patients, who are underrepresented in global donor registries. Traditional donor search strategies vary in timing and resource intensity, often leading to delays …

ca, ie (code pays fourni par la source)

Dual Targeting of Smoothened, a Key Regulator in the Hedgehog Pathway, and BCR-ABL1 Effectively Eradicates Drug-Insensitive Stem/Progenitor Cells in Chronic Myeloid Leukemia

Kelly A. Turner, Min Chen, Katharina Rothe, Donna L. Forrest et autres

Overcoming drug resistance and targeting cancer stem cells remain challenges for curative cancer treatment. In particular, patients with chronic myeloid leukemia (CML) often require lifelong therapy with ABL1 tyrosine kinase inhibitors (TKIs), partly due to a persistent population of TKI-resistant leukemic stem …

ca (code pays fourni par la source)

Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia

Andrew GR Wu, Min Chen, Athena Phoa, Zesong Yang et autres

Chronic myeloid leukemia (CML) is a leading example of a malignancy where a molecular targeted therapy revolutionized treatment but has rarely led to cures. Overcoming tyrosine kinase inhibitor (TKI) drug resistance remains a challenge in the treatment of CML. We have recently …

ca, cn (code pays fourni par la source)

Outcomes Following Second Allogeneic Stem Cell Transplant for Graft Failure or Poor Graft Function: A Single Centre Experience

Jowon Laura Kim, Moss A. Bruton Joe, Shanee Chung, Hannah Marie Cherniawsky et autres

ca (code pays fourni par la source)

Racial Disparity in Myeloablative Hematopoietic Cell Transplantation Outcomes in Patients with Hematological Malignancies Older Than 45 Years

Satarupa Mohapatra, Yasser R. Abou Mourad, Hannah Marie Cherniawsky, Shanee Chung et autres

Introduction The impact of race on outcomes of allogeneic hematopoietic cell transplants (HCT) has long been a field of research. The Center for International Blood and Marrow Transplant Research (CIBMTR) studies have shown worse survival for Blacks and Hispanics within the first …

ca (code pays fourni par la source)

Racial Disparity in Myeloablative Hematopoietic Cell Transplantation Outcomes in Patients with Hematological Malignancies Older Than 45 Years

Satarupa Mohapatra, Yasser R. Abou Mourad, Hannah Marie Cherniawsky, Shanee Chung et autres

Introduction:The impact of race on outcomes of allogeneic hematopoietic cell transplants (HCT) has long been a field of research.The Center for International Blood and Marrow Transplant Research (CIBMTR) studies have shown worse survival for Black and Hispanic patients within the first year …

ca (code pays fourni par la source)

Outcomes following second allogeneic stem cell transplant for graft failure or poor graft function: a single centre experience

Jowon Laura Kim, Moss A. Bruton Joe, Shanee Chung, Hannah Marie Cherniawsky et autres

ca (code pays fourni par la source)

Survival Outcomes for Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) in a Real-World, Retrospective Cohort Receiving Intensive Chemotherapy

Nicholas L.J. Chornenki, Afraa Mustafa Sulieman Fadul, Analiza Supan, Yasser Abou Mourad et autres

Introduction Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is defined by the presence of myelodysplasia-related cytogenetic abnormalities (MRC-cyt) or gene mutations (MRC-mut) in the 2022 International Consensus Classification (ICC) guidelines. This replaced previous definitions from the 2016 World Health Organization (WHO) guidelines …

ca, qa (code pays fourni par la source)

Routine Prophylactic Granulocyte Colony-Stimulating Factor Use Post Autologous Peripheral Blood Stem Cell Transplantation for Hodgkin's Disease, Non-Hodgkin's Lymphoma and Germ Cell Tumors Shortens Duration of Hospital Stay and Reduces Mortality: A Retrospective Single Center Experience

Neelan Sriranjan, Shanee Chung, Hannah Marie Cherniawsky, Donna L. Forrest et autres

Background: High-dose chemotherapy followed by autologous stem cell transplant (HDC/AutoSCT) is an effective therapy for various chemo-sensitive malignancies. Post-transplant complications often occur during the cytopenic period, which synthetic Granulocyte Colony Stimulating Factor (G-CSF) can shorten. G-CSF use is linked to faster engraftment …

ca (code pays fourni par la source)

CMV Reactivation Pre and Post Letermovir Prophylaxis, a Single Centre Review of Clinical Outcomes and Resource Utilization

Hannah Marie Cherniawsky, Shanee Chung, Katie Lacaria, Donna L. Forrest et autres

Introduction Prospective, randomized trials have demonstrated reduction in the incidence of clinically significant CMV infections (csCMVi) with use of letermovir prophylaxis (LP) in allogeneic hematopoietic stem cell transplant (alloHSCT). Publicly funded LP became available at our cent for routine use in late …

ca (code pays fourni par la source)